This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (12)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Corneal Disorders  • Alert me on articles by topic

Matthias G. Wirtitsch, MD; Oliver Findl, MD; Barbara Kiss, MD; Vanessa Petternel, MD; Harald Heinzl, PhD; Wolfgang Drexler, MS, PhD

Arch Ophthalmol. 2003;121:621-625.

Objective  To investigate the short-term effect of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor, on central corneal thickness in patients with cornea guttata.

Design and Methods  In this randomized, placebo-controlled, double-masked, 3-drug crossover study, 20 patients with cornea guttata (mean endothelial cell count, 1321 cells/mm²) and 8 healthy control subjects (mean endothelial cell count, 2483 cells/mm²) were included. Study medications included 2% dorzolamide hydrochloride (Trusopt 2% eye drops; Merck & Co Inc, Whitehouse Station, NJ), 0.9% saline solution (saline placebo), and a solution identical to the carrier substance of dorzolamide in Trusopt (carrier placebo). The study drugs were applied 4 times per day for 1 day only. Central corneal thickness measurements were performed using partial coherence interferometry on every study day at baseline and after 24 hours of study medication treatment.

Main Outcome Measures  Change in central corneal thickness.

Results  The mean thickening in central corneal thickness within 24 hours in eyes with cornea guttata treated with dorzolamide, saline placebo, and carrier placebo was 12.0 µm (95% confidence interval [CI], 7.0-17.1 µm), 0.6 µm (95% CI, -1.0 to 2.2 µm), and 1.3 µm (95% CI, -0.1 to 2.6 µm), respectively.

Conclusion  Application of dorzolamide for 1 day results in a slight but statistically significant thickening of central corneal thickness in patients with cornea guttata.

From the Departments of Ophthalmology (Drs Wirtitsch, Findl, Kiss, and Petternel) and Medical Computer Sciences (Dr Heinzl), and the Institute of Medical Physics (Dr Drexler), University of Vienna, Vienna, Austria. The authors have no relevant financial interest in this article.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Role of Carbonic Anhydrase IV in Corneal Endothelial HCO3- Transport
Sun et al.
IOVS 2008;49:1048-1055.
ABSTRACT | FULL TEXT  

Effect of Dorzolamide Hydrochloride on Central Corneal Thickness in Humans With Cornea Guttata
Wirtitsch et al.
Arch Ophthalmol 2007;125:1345-1350.
ABSTRACT | FULL TEXT  

HPLC Measurement of Ocular Carotenoid Levels in Human Donor Eyes in the Lutein Supplementation Era
Bhosale et al.
IOVS 2007;48:543-549.
ABSTRACT | FULL TEXT  

Brinzolamide induced reversible corneal decompensation
Zhao and Chen
Br. J. Ophthalmol. 2005;89:389-390.
FULL TEXT  

Monitoring of Rabbit Cornea Response to Dehydration Stress by Optical Coherence Tomography
Hosseini et al.
IOVS 2004;45:2555-2562.
ABSTRACT | FULL TEXT  

Endothelial Changes Associated With Topical Dorzolamide Do Appear to Be Significant
Epstein et al.
Arch Ophthalmol 2004;122:1089-1089.
FULL TEXT